May 25, 2021 -- Moderna announced its phase II/III study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint with no cases of COVID-19 observed in more than 3,700 participants ages 12 to 17 who received two doses of the vaccine.
No cases of COVID-19 were observed after two doses of the vaccine using the primary case definition, consistent with a vaccine efficacy of 100%.
The TeenCove study also showed a vaccine efficacy of 93% using the secondary U.S. Centers for Disease Control and Prevention (CDC) case definition of COVID-19, which tested for milder disease.
All participants will be monitored for one year after their second injection to assess long-term protection and safety, Moderna said.
The firm plans to submit the data to regulators globally early next month and request authorization for the vaccine for teens.
Copyright © 2021 scienceboard.net